Compare HURC & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HURC | TVGN |
|---|---|---|
| Founded | 1968 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.1M | 89.6M |
| IPO Year | N/A | N/A |
| Metric | HURC | TVGN |
|---|---|---|
| Price | $17.01 | $0.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 33.3K | ★ 689.7K |
| Earning Date | 01-09-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,554,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.19 | $0.30 |
| 52 Week High | $23.45 | $1.92 |
| Indicator | HURC | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 41.68 |
| Support Level | $16.55 | $0.31 |
| Resistance Level | $17.68 | $0.34 |
| Average True Range (ATR) | 0.84 | 0.03 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 80.73 | 32.63 |
Hurco Companies Inc is a United States-based industrial technology company. It designs, manufactures, and sells computerized machine tools, consisting mainly of vertical machining centers and turning centers, to companies in the metalworking industry through sales, service, and distribution networks. The company concentrated on designing user-friendly computer control systems that both skilled and unskilled machine tool operators can operate. It generates maximum revenue from the Computerized Machine Tools product. Geographically, It derives a majority of its revenue from the United States of America. Its product categories include 5-Axis VMC; 3-Axis VMC; Horizontal MC and Turning Centers.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.